Group 1 - The company, Giant Bio (02367), announced a share buyback plan, spending HKD 13.4408 million to repurchase 400,000 shares [1] - The buyback price per share ranges from HKD 33.48 to HKD 33.76 [1]

巨子生物(02367)发布公告，该公司于2025年12月30日斥资1344.08万港元回购40万股股份，每股回购价 格为33.48-33.76港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2025年12月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

Group 1 - The stock of Giant Bio (02367.HK) experienced a decline of over 3% in the afternoon trading session, with a current drop of 2.95% to HKD 33.54 [1] - The trading volume reached HKD 246 million [1]

Core Viewpoint - The stock of Giant Bio (02367) has experienced a decline of over 3%, with a current price of HKD 33.54, and a trading volume of HKD 246 million. The downgrade of the stock rating from "Buy" to "Neutral" by China Merchants Securities International reflects the company's ongoing challenges, including reputation issues and a significant drop in sales during the Double Eleven shopping festival [1] Group 1 - China Merchants Securities International has reduced the target price for Giant Bio from HKD 64 to HKD 35, a decrease of 45% [1] - The report highlights that the core brand, Kefu Mei, has seen a double-digit decline in sales during the recent promotional period, indicating potential market difficulties [1] - The firm believes that the current market consensus may be overly optimistic regarding the company's future performance [1] Group 2 - The investment logic for Giant Bio has shifted from growth to strategic adjustment, with a cautious outlook for the company until clearer signs of stabilization emerge [1] - Revenue forecasts for 2025-2027 have been reduced by an average of 30% to align with the management's latest guidance and a more conservative view for 2026 [1] - The sales expense ratio forecast has been increased from 36% to 38% to account for execution challenges during the adjustment phase [1]

Group 1 - The core viewpoint of the article indicates that the stock of Giant Bio (02367) has experienced a decline of over 3%, with a current price of 33.54 HKD and a trading volume of 246 million HKD [1] - China Merchants Securities International has downgraded the rating of Giant Bio from "Buy" to "Neutral" and reduced the target price by 45% from 64 HKD to 35 HKD, citing several challenges including a series of reputation crises and a double-digit decline in its core brand, Kefu Mei, during the Double Eleven shopping festival [1] - The report suggests that while the stock price has largely absorbed the related issues and the subsequent reduction in the 2025 sales guidance, the outlook for 2026 remains cautious, with the current market consensus potentially being overly optimistic [1] Group 2 - The investment logic for Giant Bio has shifted from growth to strategic adjustment, with a lack of clear catalysts for a rebound at this time, leading to a recommendation to adopt a wait-and-see approach until signs of stabilization become clearer [1] - Revenue forecasts for 2025-2027 have been reduced by an average of 30% to reflect the latest guidance from management and a more cautious outlook for 2026 [1] - The sales expense ratio forecast has been increased from 36% to 38% to account for execution challenges during the adjustment phase, with the target price based on a revised 2026 forecast price-to-earnings ratio reduced from 21.5 times to 16 times [1]

Summary of Key Points Core Viewpoint - On December 29, 55 Hong Kong-listed companies conducted share buybacks, totaling 37.9 million shares and an aggregate amount of HKD 999 million [1][2]. Group 1: Major Companies Involved in Buybacks - Tencent Holdings repurchased 1.057 million shares for HKD 636 million, with a yearly total buyback amount of HKD 78.765 billion [1][2]. - Xiaomi Group-W bought back 3.9 million shares for HKD 151 million, with a total buyback amount of HKD 6.136 billion for the year [1][2]. - China COSCO Shipping Holdings repurchased 3.46 million shares for HKD 47.9 million, with a total buyback amount of HKD 6.866 billion for the year [1][2]. Group 2: Buyback Statistics - The highest buyback amount on December 29 was from Tencent Holdings at HKD 636 million, followed by Xiaomi Group-W at HKD 151 million [1][2]. - The largest number of shares repurchased on December 29 was by Four Seasons Medicine, with 8 million shares, followed by Xiaomi Group-W and China COSCO Shipping Holdings with 3.9 million and 3.46 million shares, respectively [1][2]. Group 3: Additional Companies and Their Buyback Data - Kingsoft repurchased 713,600 shares for HKD 20 million, with a total buyback amount of HKD 33.465 million for the year [2]. - Kuaishou-W bought back 310,000 shares for HKD 20 million, with a total buyback amount of HKD 306.840 million for the year [2]. - Other notable companies include Miniso Group, which repurchased 320,600 shares for HKD 1.195 million, and Four Seasons Medicine, which had a total buyback amount of HKD 15.332 million for the year [2][3].

Group 1 - The article highlights the stock buybacks conducted by various companies on December 29, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent [1][2] - Tencent Holdings repurchased 1.057 million shares for a total of 636 million, representing 1.087% of its total share capital [2] - Other notable companies involved in buybacks include Xiaomi Group-W (01810) with 3.9 million shares repurchased for 151 million, and China Merchants Industry Holdings (01919) with 3.46 million shares for 47.9 million [2] Group 2 - The total number of shares repurchased by various companies in 2025 includes 9.987 million for Tencent, 1.42 million for Xiaomi, and 1.19 million for China Merchants Industry [2] - The buyback amounts for other companies vary, with notable figures such as Kuaishou-W (01024) repurchasing 310,000 shares for 19.97 million and Sihuan Pharmaceutical (00460) repurchasing 8 million shares for 10.01 million [2] - The data indicates a trend of companies engaging in share buybacks as a strategy to enhance shareholder value [1][2]

Core Viewpoint - The strategic partnership between Giant Bio and Nordberg Medical aims to leverage Giant Bio's patented recombinant collagen technology for global market expansion in the medical aesthetics sector, indicating a shift towards international growth opportunities [2][5][10]. Financial Performance - In the first half of the year, Giant Bio reported revenue of 31.13 billion yuan, a year-on-year increase of 22.52%, and a net profit attributable to shareholders of 11.82 billion yuan, up 20.23% [7]. - Despite positive growth, the revenue and net profit growth rates have slowed compared to previous years, where growth rates exceeded 40% [7]. - The company's gross margin for the first half of the year was 81.68%, down from previous years' figures of 85.11%, 84.14%, and 82.4% [7]. Strategic Developments - The partnership with Nordberg Medical allows Giant Bio to utilize the latter's established global marketing and sales network, facilitating quicker entry into international markets [5][10]. - Giant Bio received a medical device registration certificate for its recombinant type I α1 collagen product, marking a significant step into the professional medical sector [10][12]. Market Position and Competition - The competitive landscape in the recombinant collagen market is intensifying, with companies like Huaxi Bio and Jinbo Bio also making significant advancements [10][11]. - Jinbo Bio has established a lead in the market with multiple approved medical device registrations, highlighting Giant Bio's relatively slower progress in this area [11][12]. Stock Performance and Market Sentiment - Giant Bio's stock has seen a significant decline, dropping approximately 60% from its peak of 85.14 HKD per share earlier in the year, now trading at 34.56 HKD [12]. - The company announced a share buyback plan to repurchase up to 10% of its issued shares, reflecting confidence in its long-term strategy and growth potential [12].

Group 1 - The company, Giant Bio (02367), announced a share buyback plan on December 29, 2025, involving an expenditure of HKD 13.8144 million to repurchase 400,000 shares [1] - The buyback price is set between HKD 34.28 and HKD 34.76 per share [1]